Medicenna Therapeutics Corp. Common Shares
MDNA
MDNA was delisted on the 1st of November, 2023.
23 hedge funds and large institutions have $7.42M invested in Medicenna Therapeutics Corp. Common Shares in 2021 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 4 closing their positions.
14% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 7
8% less funds holding
Funds holding: 25 → 23 (-2)
14% less capital invested
Capital invested by funds: $8.66M → $7.42M (-$1.25M)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$2.69M |
| 2 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$618K |
| 3 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
+$227K |
| 4 |
Renaissance Technologies
New York
|
+$181K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$9.69K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
ACT Capital Management
Wayne,
Pennsylvania
|
-$410K |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$101K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$77.6K |
| 4 |
DC
Davenport & Co
Richmond,
Virginia
|
-$77K |
| 5 |
Morgan Stanley
New York
|
-$64.8K |
MDNA Hedge Fund Activity: Q4 2021 in Review
23 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Medicenna Therapeutics Corp. Common Shares (MDNA) for Q4 2021, worth a combined $7.42M — down 14% from $8.66M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of MDNA and 2 opened new positions — a net loss of 2 holders — while 7 trimmed existing stakes and 8 added.
The largest buyer was AIGH Capital Management, adding an estimated $2.69M. The largest seller was ACT Capital Management, cutting an estimated $410K.
- 23 institutional investors held Medicenna Therapeutics Corp. Common Shares (MDNA) as of Q4 2021, down from 25 in Q3 2021.
- Funds reported $7.42M of Medicenna Therapeutics Corp. Common Shares stock for Q4 2021, down 14% quarter-over-quarter.
- 2 funds opened new Medicenna Therapeutics Corp. Common Shares positions in Q4 2021 and 4 closed out, a net change of -2 holders.
- The largest Medicenna Therapeutics Corp. Common Shares buyer in Q4 2021 was AIGH Capital Management, an estimated $2.69M added.
- The largest Medicenna Therapeutics Corp. Common Shares seller in Q4 2021 was ACT Capital Management, an estimated $410K sold.
Based on aggregated 13F filings for Q4 2021.